Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis

The chimeric anti-CD20 antibody rituximab has demonstrated good efficacy as an off-label treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), while the humanized anti-CD20 antibody ocrelizumab has been approved for treatment of multiple sclerosis (MS), whereas there is no evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Auer, Michael, Hegen, Harald, Hotter, Anna, Löscher, Wolfgang, Berek, Klaus, Zinganell, Anne, Fava, Elena, Rhomberg, Paul, Deisenhammer, Florian, Di Pauli, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966083/
https://www.ncbi.nlm.nih.gov/pubmed/35370432
http://dx.doi.org/10.1177/11795735221084837
_version_ 1784678578398429184
author Auer, Michael
Hegen, Harald
Hotter, Anna
Löscher, Wolfgang
Berek, Klaus
Zinganell, Anne
Fava, Elena
Rhomberg, Paul
Deisenhammer, Florian
Di Pauli, Franziska
author_facet Auer, Michael
Hegen, Harald
Hotter, Anna
Löscher, Wolfgang
Berek, Klaus
Zinganell, Anne
Fava, Elena
Rhomberg, Paul
Deisenhammer, Florian
Di Pauli, Franziska
author_sort Auer, Michael
collection PubMed
description The chimeric anti-CD20 antibody rituximab has demonstrated good efficacy as an off-label treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), while the humanized anti-CD20 antibody ocrelizumab has been approved for treatment of multiple sclerosis (MS), whereas there is no evidence for its use in CIDP so far. We present a patient suffering from CIDP and MS, both refractory to standard treatment and both showing marked improvement on ocrelizumab. To the best of our knowledge, this is a unique report of CIDP with an almost full electrophysiological recovery on ocrelizumab which could be considered as a potential treatment option for refractory CIDP.
format Online
Article
Text
id pubmed-8966083
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89660832022-03-31 Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis Auer, Michael Hegen, Harald Hotter, Anna Löscher, Wolfgang Berek, Klaus Zinganell, Anne Fava, Elena Rhomberg, Paul Deisenhammer, Florian Di Pauli, Franziska J Cent Nerv Syst Dis Case Report The chimeric anti-CD20 antibody rituximab has demonstrated good efficacy as an off-label treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), while the humanized anti-CD20 antibody ocrelizumab has been approved for treatment of multiple sclerosis (MS), whereas there is no evidence for its use in CIDP so far. We present a patient suffering from CIDP and MS, both refractory to standard treatment and both showing marked improvement on ocrelizumab. To the best of our knowledge, this is a unique report of CIDP with an almost full electrophysiological recovery on ocrelizumab which could be considered as a potential treatment option for refractory CIDP. SAGE Publications 2022-03-28 /pmc/articles/PMC8966083/ /pubmed/35370432 http://dx.doi.org/10.1177/11795735221084837 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Auer, Michael
Hegen, Harald
Hotter, Anna
Löscher, Wolfgang
Berek, Klaus
Zinganell, Anne
Fava, Elena
Rhomberg, Paul
Deisenhammer, Florian
Di Pauli, Franziska
Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
title Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
title_full Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
title_fullStr Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
title_full_unstemmed Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
title_short Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
title_sort recovery of chronic inflammatory demyelinating polyneuropathy on treatment with ocrelizumab in a patient with co-existing multiple sclerosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966083/
https://www.ncbi.nlm.nih.gov/pubmed/35370432
http://dx.doi.org/10.1177/11795735221084837
work_keys_str_mv AT auermichael recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT hegenharald recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT hotteranna recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT loscherwolfgang recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT berekklaus recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT zinganellanne recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT favaelena recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT rhombergpaul recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT deisenhammerflorian recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis
AT dipaulifranziska recoveryofchronicinflammatorydemyelinatingpolyneuropathyontreatmentwithocrelizumabinapatientwithcoexistingmultiplesclerosis

Ejemplares similares